Reply to D.H. Roukos and D.A.X. Schinagl et al

Journal of Clinical Oncology

Volumn 28, Issue 17, 2010, Pages

  Gonzalez Angulo, Ana M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; FOLLOW UP; HAZARD RATIO; HUMAN; KAPLAN MEIER METHOD; LETTER; MASTECTOMY; MULTIVARIATE ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY;

EID: 79951795889     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.0339     Document Type: Letter

References (12)

1. Roukus DH: Beyond HER2 and trastuzumab: Heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer. J Clin Oncol 28:e279-e280, 2010
2. Schinagl DAX, van Tienhoven G: Breast cancer: Disentangling the intricate web. J Clin Oncol 28:e281, 2010
3. Gonzalez-Angulo AM, Litton JK, Broglio KR, et al: High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27:5700-5706, 2009
4. Black D, Younger J, Martei Y, et al: Recurrence risk in T1a-b, node-negative, HER2 positive breast cancer. Breast Cancer Res Treat 100:s92, 2006 (suppl 1; abstr 2037)
5. Joensuu H, Isola J, Lundin M, et al: Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: A nationwide population-based study. Clin Cancer Res 9:923-930, 2003 (Pubitemid 36323694)
6. Tovey SM, Brown S, Doughty JC, et al: Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. Br J Cancer 100:680-683, 2009
7. Chia S, Norris B, Speers C, et al: Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 26:5697-5704, 2008
8. Curigliano G, Viale G, Bagnardi V, et al: Clinical relevance of HER2 overexpression/amplification in patients with small tumor size (pT1a-b) and node-negative breast cancer. J Clin Oncol 27:5693-5699, 2009
9. National Comprehensive Cancer Network. www.nccn.org
10. Untch M, Gelber RD, Jackisch C, et al: Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 19:1090-1096, 2008 (Pubitemid 351796334)
11. Rodrigues MJ, Wassermann J, Albiges-Sauvin L, et al: Treatment of node-negative infra-centrimetric HER2+ invasive breast carcinomas: A joint AERIO/REMAGUS study. J Clin Oncol 27:10s, 2009 (suppl; abstr 517)
12. Albert JM, Gonzalez-Angulo AM, Guray M: Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer. Int J Radiat Oncol Biol Phys (in press)